Author(s): Jacquillat C, Baillet F, Weil M, Auclerc G, Housset M,
Abstract Share this page
Abstract Ninety-eight patients with locally advanced breast cancer (Stage IIIA-IIIB) were entered into a pilot study combining intensive induction (neoadjuvant) chemotherapy (VTMFAP) with or without hormonochemotherapy, external and interstitial radiotherapy, and consolidation chemotherapy with or without hormonochemotherapy. Tumor regression over 50\% was observed in 91\% patients after chemotherapy, and complete clinical remission occurred in 100\% patients after irradiation. The rate of local relapse is 13\%. The 3-year disease-free survival is 62\% and 3-year global survival is 77\%. Initial chemotherapeutic tumor regression greater than 75\% is the main predictive factor for disease-free survival.
This article was published in Cancer
and referenced in